New vaccine helps the body identify the brain cancer cells

The test showed that the brain helps patients with glioblastoma to double the life expectancy after surgery.

Glioblastoma is the most dangerous form of adults, often treated with surgery combined with radiotherapy, chemotherapy but the effectiveness is limited because the disease is difficult to intervene. On average, patients after surgery only live 15-17 months.

Now, this situation may change thanks to the new vaccine called DCVax . In Translational Medicine, scientists claim that DCVax has entered the third phase of testing and has shown a long-lasting effect on life for people with glioblastoma.

DCVax vaccine offers hope for brain cancer patients.(Photo: Reuters).

According to the BBC, DCVax works by targeting the dendritic immune cells of the human body, helping them to identify and kill tumors. Because the nature helps the body get used to cancer cells, DCVax is classified as a vaccine, not a drug. The vaccine has been studied for 11 years and has just entered the third phase of testing on 331 volunteers from the UK, USA, Canada, and Germany. Of these, 232 patients were injected with DCVax while the rest used placebo and conventional therapy.

The results showed that the average survival of volunteers using DCVax after surgery was 23 months, 100 people reached more than 40.5 months. Particularly, one case is 7 years old.

As a DCVAx tester, Kat Charles (UK) was reported to have only 3 months to live after receiving a diagnosis of brain cancer in 2014. "They said nothing could be done," the 36-year-old woman said. share. Going through the usual methods and testing another drug, Kat and her husband Jason decided to switch to DCVax. At the end of the course, Kat's tumor completely disappeared.

"DCVax can do what others believe is impossible" , Jason rejoices. "Without this method, I lost my wife and children who lost my mother."

Currently, Kat continues to be vaccinated regularly. "I went to London, got vaccinated and went home. The medicine did not cause side effects. It was great," said the happy female patient.

Keyoumars Ashkan, Professor of Neurosurgery from King University Hospital, who oversees DCVax on brain cancer vaccination, has brought new hope to patients as well as doctors struggling with the disease. This terrible."There must be further consideration but this is really a breakthrough in the treatment of neuroblastoma ," concluded Ashkan.